Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pluri Inc. (PLUR)

1.15   -0.04 (-3.36%) 01-27 15:57
Open: 1.2 Pre. Close: 1.19
High: 1.2 Low: 1.145
Volume: 22,086 Market Cap: 45(M)

Technical analysis

as of: 2023-01-27 4:47:08 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.44     One year: 1.69
Support: Support1: 0.89    Support2: 0.74
Resistance: Resistance1: 1.23    Resistance2: 1.44
Pivot: 1.16
Moving Average: MA(5): 1.18     MA(20): 1.11
MA(100): 0.87     MA(250): 1.24
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 40.1     %D(3): 44.6
RSI: RSI(14): 54.9
52-week: High: 2.21  Low: 0.64
Average Vol(K): 3-Month: 81 (K)  10-Days: 81 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PLUR ] has closed above bottom band by 46.6%. Bollinger Bands are 54.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.2 - 1.21 1.21 - 1.21
Low: 1.13 - 1.14 1.14 - 1.14
Close: 1.14 - 1.15 1.15 - 1.16

Company Description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Headline News

Fri, 27 Jan 2023
TSX Venture Exchange Stock Maintenance Bulletins - Investing News Network

Fri, 27 Jan 2023
Photo gallery: 'Sailor Moon' fans bring the superhero to a rave in ... - Mashable

Fri, 27 Jan 2023
Plurilock Security (PLUR.V) builds a safe workplace without ... - Equity.Guru

Mon, 23 Jan 2023
Pluri Inc (Pluristem Therapeutics) Holds No Hope For The Weak - Seeking Alpha

Tue, 17 Jan 2023
Remarks by President Biden and Vice President Harris Honoring the ... - The White House

Mon, 16 Jan 2023
Plurilock Security (PLUR.V) releases application powered by ChatGPT - Equity.Guru

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 2.777e+007 (%)
% Held by Institutions 7.5 (%)
Shares Short 165 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.054e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -17
Return on Assets (ttm) 774.7
Return on Equity (ttm) -32.2
Qtrly Rev. Growth 234000
Gross Profit (p.s.) 0
Sales Per Share -52.93
EBITDA (p.s.) 133714
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -37 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 143080
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.